Company intelligence / Profile preview

Leadingtac

Shanghai, Shanghai, Chinaen.leadingtac.com ↗

Ownership: Private
Development stage: Other

Overview

LT-002, the company's lead IRAK4 degrader, has received FDA approval to enter Phase 1 clinical trials in May 2023 and NMPA approval for Phase 1 clinical trials in October 2023. As of April 2025, the company has advanced to Phase 2 trials for Dermatitis (Atopic) and Hidradenitis Suppurativa.

Therapeutic areas: OncologyDermatologyHematology
Modalities: Small moleculesProtein degraders (PROTACs)
Industry: Biotech

Drug pipeline

6 assets

LT-002

5 more assets in the full pipeline.

Partnerships

BioDuro-Sundia (chemistry partner)

Beyond the preview

Go deeper on Leadingtac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leadingtac.